Nimbus hopes to strike thrice
But the group has chosen the tough immuno-oncology space for its third attempt to woo the big players.
Takeda Tyks the deal-making box
For $4bn up front, Takeda buys into the Tyk2 mechanism – and Nimbus and its backers get a huge pay day.
Nimbus hopes to best Bristol’s Sotyktu
Nimbus aims to push Tyk2 inhibition to the limit with its more selective project, but others have a similar idea.
Esker joins the Tyk2 race
The new group reckons it has the most selective Tyk2 inhibitor yet. Patenting it is another issue.
Bristol’s Tyk2 ticks the boxes
Bristol’s new oral psoriasis option looks much better than Otezla, but competing against injectables could be tricky.
Who will follow Curis’s clinical validation?
As Curis clinically backs a novel oncology mechanism, several companies might review their own similarly acting projects.
After Takeda endorsement Curadev’s Sting attracts Bayer
The coronavirus pandemic notwithstanding, Curadev snares its second Sting partner.
